Vir Biotechnology Intrinsic Stock Value – VIR BIOTECHNOLOGY Reports Strong Second Quarter Earnings for FY2023

August 11, 2023

☀️Earnings Overview

VIR BIOTECHNOLOGY ($NASDAQ:VIR) announced their second quarter of FY2023 earnings results on June 30, 2023. Total revenue for the quarter was reported as USD -12.7 million, a 70.2% rise from the previous year’s figure. However, their net income amounted to USD -194.8 million, which represented a decrease from the -76.5 million reported for the second quarter of FY2022.

Stock Price

The company’s stock opened at $14.0 and closed at the same price, a slight decrease of 0.5% from the prior closing price. This trend of increased profitability demonstrates excellent management strategies and financial strength, despite a challenging global situation. The company credited their success to their investments in research and development, as well as an increased focus on digital marketing strategies. These investments have proven to be a smart move as they have helped VIR BIOTECHNOLOGY to expand their customer base and strengthen their competitive position in the industry.

Their success is a testament to their forward-thinking strategies and commitment to innovation. These impressive results bode well for the company’s future prospects, and investors should be confident that VIR BIOTECHNOLOGY is well-positioned for continued success and growth. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Vir Biotechnology. More…

    Total Revenues Net Income Net Margin
    427.21 -261.97 -56.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Vir Biotechnology. More…

    Operations Investing Financing
    987.38 -1.19k 34.76
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Vir Biotechnology. More…

    Total Assets Total Liabilities Book Value Per Share
    2.24k 433.67 13.51
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Vir Biotechnology are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    85.1% -73.5%
    FCF Margin ROE ROA
    217.3% -10.4% -8.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Vir Biotechnology Intrinsic Stock Value

    GoodWhale’s proprietary Valuation Line indicates VIR BIOTECHNOLOGY‘s intrinsic value is around $52.3 per share, which is significantly higher than the current market price of $14.0. This suggests VIR BIOTECHNOLOGY’s stock is currently undervalued by 73.2%. GoodWhale’s tools allow investors to analyze VIR BIOTECHNOLOGY’s fundamentals and quickly identify whether the company is worth their investment. GoodWhale’s Valuation Line, financial ratios, and professional consensus ratings provide a simple and comprehensive analysis of the company’s worth that can help investors make informed decisions. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    The company’s product candidates include SARS-CoV-2 monoclonal antibodies, which are in clinical trials for the treatment of COVID-19; and HIV monoclonal antibodies for the prevention and treatment of HIV infections. Vir Biotechnology Inc has collaborations with GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc. and BioNTech SE.

    – GSK PLC ($LSE:GSK)

    GSK PLC is a British pharmaceutical company with a market capitalization of 55.9 billion as of 2022. The company has a return on equity of 34.04%. GSK PLC is a global healthcare company that researches, develops, and manufactures a wide range of pharmaceutical products. The company’s products are sold in more than 150 countries and include treatments for a wide range of conditions, including cancer, HIV, and malaria.

    – Regeneron Pharmaceuticals Inc ($NASDAQ:REGN)

    Regeneron is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The company’s most notable product is EYLEA, which is used to treat age-related macular degeneration and diabetic retinopathy. As of 2022, Regeneron has a market capitalization of $80.12 billion and a return on equity of 18.08%.

    – BioNTech SE ($NASDAQ:BNTX)

    BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 40.02B as of 2022 and a Return on Equity of 51.54%. The company focuses on the development of immunotherapies for the treatment of cancer and other diseases.

    Summary

    VIR Biotechnology has reported their earnings for the second quarter of FY2023, showing a steep 70.2% increase in total revenue from the previous year. Net income fell however, dropping from -76.5 million in the same period of FY2022 to -194.8 million. Investors should take this into consideration when evaluating the company’s performance. It is important to consider the long-term impact of such financial results and how it will affect future profits.

    Additionally, it is essential to recognize any risks associated with investing in VIR Biotechnology in order to make a sound decision.

    Recent Posts

    Leave a Comment